Mark Johnson to Transplantation, Heterologous
This is a "connection" page, showing publications Mark Johnson has written about Transplantation, Heterologous.
Connection Strength
0.103
-
Kim H, Huang W, Jiang X, Pennicooke B, Park PJ, Johnson MD. Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci U S A. 2010 Feb 02; 107(5):2183-8.
Score: 0.082
-
Low JA, Johnson MD, Bone EA, Dickson RB. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res. 1996 Jul; 2(7):1207-14.
Score: 0.008
-
Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest. 1993 Dec; 92(6):2569-76.
Score: 0.007
-
Kurebayashi J, McLeskey SW, Johnson MD, Lippman ME, Dickson RB, Kern FG. Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and LacZ. Cancer Res. 1993 May 01; 53(9):2178-87.
Score: 0.006